Comment from National Multiple Sclerosis Society

Summary: The National Multiple Sclerosis Society supports the FDA's patient-focused drug development (PFDD) initiative, highlighting its value in capturing lived experience to inform clinical trial design, endpoints, and benefit-risk assessments. They urge the FDA to ensure equitable access to these meetings for smaller organizations and to provide more transparent feedback on how patient input is integrated into regulatory decisions.